Reference number(s)
3042-H

SPECIALTY QUANTITY LIMIT PROGRAM

TAKHZYRO (lanadelumab-flyo)

I. PROGRAM DESCRIPTION

The standard limit is designed to allow a quantity sufficient for the most common uses of the medication. The recommended dosing parameters for all FDA-approved indications fall within the standard limits. Coverage of an additional quantity may be reviewed on a case-by-case basis upon request.

II. COVERED QUANTITIES

Medication	Standard Limit	FDA-recommended dosing
Takhzyro 300mg/2mL vial	2 vials per 28 days	300 mg every 2 weeks 300 mg every 4 weeks may be considered if the patient is well-controlled for more than 6 months

III. REFERENCES

1. Takhzyro™ [package insert]. Lexington, MA: Dyax Corp.; November 2018.

CVS caremark™